Zurich, Switzerland
Zurich, Switzerland

Time filter

Source Type

Milleret V.,University of Zürich | Buzzi S.,Qvanteq Inc. | Gehrig P.,ETH Zurich | Ziogas A.,University of Zürich | And 6 more authors.
Acta Biomaterialia | Year: 2015

Biomaterials upon implantation are immediately covered by blood proteins which direct the subsequent blood activation. These early events determine the following cascade of biological reactions and consequently the long-term success of implants. The ability to modulate surface properties of biomaterials is therefore of considerable clinical significance. Goal of this study was an in-depth understanding of the biological response to cobalt chromium stent alloys with engineered surface oxide layers, which showed altered body reactions in vivo. We analyzed in vitro the biological events following initial blood contact on engineered cobalt chromium surfaces featuring said oxide layers. Surface-specific blood reactions were confirmed by scanning electron microscopy and the adsorbed protein layers were characterized by mass spectrometry. This powerful proteomics tool allowed the identification and quantification of over hundred surface-adhering proteins. Proteins associated with the coagulation cascade, platelet adhesion and neutrophil function correlated with the various blood surface activations observed. Furthermore, results of pre-coated surfaces with defined fibrinogen-albumin mixtures suggest that neutrophil adhesion was controlled by fibrinogen orientation and conformation rather than quantity. This study highlights the importance of controlling the biological response in the complex protein-implant surface interactions and the potential of the surface modifications to improve the clinical performance of medical implants. Statement of Significance The blood contact activation of CoCr alloys is determined by their surface oxide layer properties. Modifications of the oxide layer affected the total amount of adsorbed proteins and the composition of the adsorbed protein layer. Additionally fibrinogen coatings mediated the surface-dependent neutrophil adhesion in a concentration-independent manner, indicating the influence of conformation and/or orientation of the adsorbed protein. Despite the complexity of protein-implant interactions, this study highlights the importance of understanding and controlling mechanisms of protein adhesion in order to improve and steer the performance of medical implants. It shows that modification of the surface oxide layer is a very attractive strategy to directly functionalize metallic implant surfaces and optimize their blood interaction for the desired orthopedic or cardiovascular applications. © 2015 Acta Materialia Inc.


PubMed | University of Zürich, ETH Zurich and Qvanteq Inc.
Type: | Journal: Acta biomaterialia | Year: 2015

Biomaterials upon implantation are immediately covered by blood proteins which direct the subsequent blood activation. These early events determine the following cascade of biological reactions and consequently the long-term success of implants. The ability to modulate surface properties of biomaterials is therefore of considerable clinical significance. Goal of this study was an in-depth understanding of the biological response to cobalt chromium stent alloys with engineered surface oxide layers, which showed altered body reactions in vivo. We analyzed in vitro the biological events following initial blood contact on engineered cobalt chromium surfaces featuring said oxide layers. Surface-specific blood reactions were confirmed by scanning electron microscopy and the adsorbed protein layers were characterized by mass spectrometry. This powerful proteomics tool allowed the identification and quantification of over hundred surface-adhering proteins. Proteins associated with the coagulation cascade, platelet adhesion and neutrophil function correlated with the various blood surface activations observed. Furthermore, results of pre-coated surfaces with defined fibrinogen-albumin mixtures suggest that neutrophil adhesion was controlled by fibrinogen orientation and conformation rather than quantity. This study highlights the importance of controlling the biological response in the complex protein-implant surface interactions and the potential of the surface modifications to improve the clinical performance of medical implants.The blood contact activation of CoCr alloys is determined by their surface oxide layer properties. Modifications of the oxide layer affected the total amount of adsorbed proteins and the composition of the adsorbed protein layer. Additionally fibrinogen coatings mediated the surface-dependent neutrophil adhesion in a concentration-independent manner, indicating the influence of conformation and/or orientation of the adsorbed protein. Despite the complexity of protein-implant interactions, this study highlights the importance of understanding and controlling mechanisms of protein adhesion in order to improve and steer the performance of medical implants. It shows that modification of the surface oxide layer is a very attractive strategy to directly functionalize metallic implant surfaces and optimize their blood interaction for the desired orthopedic or cardiovascular applications.


Milleret V.,University of Zürich | Ziogas A.,University of Zürich | Buzzi S.,Qvanteq Inc. | Heuberger R.,RMS Foundation | And 2 more authors.
Journal of Biomedical Materials Research - Part B Applied Biomaterials | Year: 2015

CoCr alloys, in particular MP35N and L605, are extensively used in biomedical implants, for example for coronary stents. In practice, these alloys present a moderately hydrophobic surface which leads to significant platelet adhesion and consequently to risk of early thrombosis or in-stent restenosis. Surface modification of biomedical implants is known to alter their biological performances. In this study we focused on the alteration of in vitro biological responses of human cells contacting CoCr surfaces with engineered oxide layers. XPS analysis was performed to determine the composition of the oxide layer of differently treated CoCr while the bulk properties were not modified. An extensive characterization of the surfaces was performed looking at surface roughness, wettability and charge. After static exposure to blood, strongly reduced platelet and increased polymorphonuclear neutrophil adhesion were observed on treated versus untreated surfaces. Comparisons of treated and untreated samples provide evidence for wettability being an important player for platelet adhesion, although multiple factors including surface oxide chemistry and charge might control polymorphonuclear neutrophil adhesion. The differently treated surfaces were shown to be equally suitable for endothelial cell proliferation. We herein present a novel approach to steer biological properties of CoCr alloys. By adjusting their oxide layer composition, substrates were generated which are suitable for endothelial cell growth and at the same time show an altered (reduced) blood contact activation. Such treatments are expected to lead to stents of highly reproducible quality with minimal thrombogenicity and in-stent restenosis, while maintaining rapid re-endothelialization after coronary angioplasty. © 2014 Wiley Periodicals, Inc. All rights reserved.


Patent
Qvanteq Inc. | Date: 2013-05-31

A packaging system comprises having packaging for an implant (6) and/or a catheter (7), which has a receptacle (1) for the implant (6) and/or the catheter (7) which receptacle has at its distal end a closure (2) and an opening or actuating mechanism with a closable and expandable axial passage (5). An insertion aid for the insertion of a removal device and/or a wire (14) into an inner lumen of the implant and/or catheter can be provided by a sleeve-like insertion element (10, 100, 101, 102, 103, 104), which is arranged at least partially within the axial passage (5) in the closure (2), or is formed by the closing element. An opposite, distal end forms an insertion opening (120) for the removal device and/or the wire (14) into the insertion element. The packaging can include at a rear end a transport device (7) for moving the implant, or the device for use of the implant, relative to the packaging through the closure. A coupling device (15) with a passage (17) which device moves relative to a receptacle in the packaging can connect to the closure, which passage can be connected to an inlet port (12) of a container or an insertion system (11).


Patent
Qvanteq Inc. | Date: 2014-11-12

An implant for implantation into a body is provided with a surface that is provided for contact with the body or a bodily fluid when implanted and which surface has a first surface charge when in a first state. The surface assumes a second state having a second surface charge as a result of surface treatment, the second surface charge being a lower positive surface charge or a higher negative surface charge than the first surface charge. The implant is used for regulating an adsorption of proteins on the surface of the implant in terms of type, quantity and/or conformation of certain proteins by means of a defined second state of the surface, which has a defined second surface charge and/or a defined predetermined composition of an oxide layer of the surface.


Patent
Qvanteq Inc. | Date: 2014-11-12

An implant for vascular implantation in a body is provided with a surface which, in the implanted state, is provided for contact with the body or with a bodily fluid and which is at least for the most part hydrated. The surface is advantageously provided as a bare metal surface of a chromium-containing alloy. The vascular implant is used to regulate an adsorption of proteins on the surface of the implant, in respect of the type, quantity and/or conformation of certain proteins, by a defined surface which is at least for the most part hydrated.


Qvanteq Inc. | Entity website

Investors Investors Qvanteq has completed two financing rounds (series A and B) with private investors mainly. For inquiries please contact the company


Qvanteq Inc. | Entity website


Qvanteq Inc. | Entity website

16. April 2015 Red Herring 100 Europe Winner Qvanteq AG chosen as a 2015 Red Herring Europe Winner Amsterdam, Netherlands Red Herring announced its Red Herring Europe award winners today, recognizing Europes leading private companies and celebrating these startups innovations and technologies across their respective industries ...

Loading Qvanteq Inc. collaborators
Loading Qvanteq Inc. collaborators